{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:03Z","timestamp":1787009043262,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extended spectrum \u03b2-lactamase (ESBL) and AmpC-producing Gram-negative bacilli contribute significantly to the antimicrobial resistance (AMR) burden worldwide. Temocillin is an intravenous semisynthetic antibiotic that is stable to hydrolysis by ESBLs and AmpC. Temocillin may be a treatment option for serious infections due to these organisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates from the MERINO trial were collected. The majority originated from the urinary tract. Isolates had previously undergone whole genome sequencing (WGS) to identify antimicrobial resistance genes. Temocillin minimum inhibitory concentration (MIC) values were determined by broth microdilution (BMD) with a concentration range of 2 to 128\u2009mg\/L. A recent EUCAST guideline has recommended clinical breakpoints for urinary E. coli, Klebsiella spp. (except K. aerogenes) and Proteus mirabilis (resistant &amp;gt;16\u2009mg\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>317 index bloodstream isolates (275 E. coli and 42 K. pneumoniae) were used. The frequency of \u03b2-lactamases among isolates was: CTX-M-15 (56%), OXA-1 (31%), CTX-M-27 (14%), CTX-M-14 (12%) and CMY-2 (8%). Overall, 95% of isolates were susceptible, increased exposure according to EUCAST clinical breakpoints v11.0. Summary MIC values were obtained: MIC50 was 8\u2009mg\/L and MIC90 was16 mg\/L (range \u22642 to \u2265128\u2009mg\/L) and did not differ markedly between species. Higher MIC values were seen among isolates that produced more than one \u03b2-lactamase but this did not appear to be specific to a single \u03b2-lactamase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Temocillin demonstrated favourable in vitro activity against ceftriaxone-resistant Enterobacterales bloodstream isolates and may be a suitable agent to be trialled for treatment of serious infections due to these organisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlab192","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T07:06:28Z","timestamp":1639292788000},"source":"Crossref","is-referenced-by-count":8,"title":["Activity of temocillin against third-generation cephalosporin-resistant\n                    <i>Escherichia coli<\/i>\n                    and\n                    <i>Klebsiella pneumoniae<\/i>\n                    bloodstream isolates from a clinical trial"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7262-7529","authenticated-orcid":false,"given":"Adam G","family":"Stewart","sequence":"first","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Australia"},{"name":"Department of Infectious Diseases, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"},{"name":"Central Microbiology, Pathology Queensland, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Henderson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Australia"},{"name":"Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J","family":"Bauer","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4437","authenticated-orcid":false,"given":"David L","family":"Paterson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Australia"},{"name":"Department of Infectious Diseases, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-0345","authenticated-orcid":false,"given":"Patrick N A","family":"Harris","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Australia"},{"name":"Central Microbiology, Pathology Queensland, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"2022031017574798300_dlab192-B1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2022031017574798300_dlab192-B2","doi-asserted-by":"crossref","first-page":"e120\u20134","DOI":"10.1016\/j.ijid.2012.09.008","article-title":"Clinical outcome of extended-spectrum \u03b2-lactamase-producing Escherichia coli bacteremia in an area with high endemicity","volume":"17","author":"To","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2022031017574798300_dlab192-B3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022031017574798300_dlab192-B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1471-2334-12-245","article-title":"Impact of empirical treatment in extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study","volume":"12","author":"Peralta","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2022031017574798300_dlab192-B5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2022031017574798300_dlab192-B6","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69 Suppl S8","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022031017574798300_dlab192-B7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/26.6.735","article-title":"Temocillin","volume":"26","author":"Spencer","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B9","author":"EUCAST","year":"2019"},{"key":"2022031017574798300_dlab192-B10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jac\/dkx466","article-title":"Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27","volume":"73","author":"Harris","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B11","author":"International Organization for Standardization","year":"2019"},{"key":"2022031017574798300_dlab192-B12","author":"EUCAST. Clinical breakpoints and dosing of antibiotics"},{"key":"2022031017574798300_dlab192-B13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/48.suppl_1.29","article-title":"The development of the BSAC standardized method of disc diffusion testing","volume":"48 Suppl 1","author":"Andrews","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s10096-020-03844-5","article-title":"Activity of temocillin against ESBL-, AmpC-, and\/or KPC-producing Enterobacterales isolated in Poland","volume":"39","author":"Kuch","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022031017574798300_dlab192-B15","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s10096-017-3091-8","article-title":"Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong","volume":"36","author":"Ip","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022031017574798300_dlab192-B16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","article-title":"The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011","volume":"48","author":"Zykov","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"2022031017574798300_dlab192-B18","doi-asserted-by":"crossref","first-page":"115368","DOI":"10.1016\/j.diagmicrobio.2021.115368","article-title":"Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France","volume":"100","author":"Farfour","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022031017574798300_dlab192-B19","doi-asserted-by":"crossref","first-page":"40208","DOI":"10.1038\/srep40208","article-title":"Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic","volume":"7","author":"Chalhoub","year":"2017","journal-title":"Sci Rep"},{"key":"2022031017574798300_dlab192-B20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dku542","article-title":"Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15","volume":"70","author":"Soubirou","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkp208","article-title":"Clinical efficacy of temocillin","volume":"64","author":"Gupta","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022031017574798300_dlab192-B23","doi-asserted-by":"crossref","first-page":"e0248177","DOI":"10.1371\/journal.pone.0248177","article-title":"Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum \u03b2-lactamase producing Escherichia coli in a mouse model","volume":"16","author":"Chenouard","year":"2021","journal-title":"PLoS One"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/1\/dlab192\/42807154\/dlab192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/1\/dlab192\/42807154\/dlab192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:58:10Z","timestamp":1646917090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab192\/6485044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab192","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,28]]},"article-number":"dlab192"}}